These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 8479525)

  • 1. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
    Oliner JD; Pietenpol JA; Thiagalingam S; Gyuris J; Kinzler KW; Vogelstein B
    Nature; 1993 Apr; 362(6423):857-60. PubMed ID: 8479525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants.
    Brown DR; Deb D; Frum R; Hickes L; Munoz R; Deb S; Deb SP
    Int J Oncol; 2001 Mar; 18(3):449-59. PubMed ID: 11179471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
    Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
    Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.
    Juven T; Barak Y; Zauberman A; George DL; Oren M
    Oncogene; 1993 Dec; 8(12):3411-6. PubMed ID: 8247544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of p53-mediated transcription by MDM2: a dual mechanism.
    Thut CJ; Goodrich JA; Tjian R
    Genes Dev; 1997 Aug; 11(15):1974-86. PubMed ID: 9271120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetic approach to mapping the p53 binding site in the MDM2 protein.
    Freedman DA; Epstein CB; Roth JC; Levine AJ
    Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.
    Knights CD; Liu Y; Appella E; Kulesz-Martin M
    J Biol Chem; 2003 Dec; 278(52):52890-900. PubMed ID: 14555661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein.
    Dobbelstein M; Wienzek S; König C; Roth J
    Oncogene; 1999 Mar; 18(12):2101-6. PubMed ID: 10321734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between the retinoblastoma protein and the oncoprotein MDM2.
    Xiao ZX; Chen J; Levine AJ; Modjtahedi N; Xing J; Sellers WR; Livingston DM
    Nature; 1995 Jun; 375(6533):694-8. PubMed ID: 7791904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
    Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
    Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
    Dubs-Poterszman MC; Tocque B; Wasylyk B
    Oncogene; 1995 Dec; 11(11):2445-9. PubMed ID: 8570197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
    Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
    Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of a gene encoding a p53-associated protein in human sarcomas.
    Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B
    Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.
    Martin K; Trouche D; Hagemeier C; Sørensen TS; La Thangue NB; Kouzarides T
    Nature; 1995 Jun; 375(6533):691-4. PubMed ID: 7791903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mdm2 proto-oncogene.
    Haines DS
    Leuk Lymphoma; 1997 Jul; 26(3-4):227-38. PubMed ID: 9322885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
    Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
    Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
    Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ
    Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
    Lin J; Chen J; Elenbaas B; Levine AJ
    Genes Dev; 1994 May; 8(10):1235-46. PubMed ID: 7926727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.